Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017 (2017), Article ID 5235163, 4 pages
https://doi.org/10.1155/2017/5235163
Case Report

Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder

Department of Internal Medicine, Division of Medical Oncology, University of Florida COM, Jacksonville, FL, USA

Correspondence should be addressed to Jason Hew; moc.oohay@rukraht

Received 23 January 2017; Accepted 22 March 2017; Published 30 April 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Jason Hew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Soumerai, A. R. Sohani, and J. S. Abrahamson, “Diagnosis and management of Castleman disease,” Cancer Control, vol. 21, no. 4, pp. 266–278, Oct 2014. View at Google Scholar
  2. M. Flejsierowicz, M. Ahmed, P. Kotov, and C. Cheng, “Successful treatment of aggressive HIV associated multicentric Castlemans Disease: a case report,” Wis Med J., vol. 107, no. 4, pp. 191–194, 2008. View at Google Scholar
  3. E. E. Mylona, I. G. Baraboutis, L. J. Lekakis, O. Georgiou, V. Papastamopoulos, and A. Skoutelis, “Multicentric castlemans disease in HIV infection a systematic review of the literature,” AIDS Reviews, vol. 10, no. 1, pp. 25–35, 2008. View at Google Scholar
  4. A. Waterston and M. Bower, “Fifty years of multicentric Castleman disease,” Acta Oncol, vol. 43, no. 8, pp. 698–704, 2004. View at Google Scholar
  5. D. C. Fajgenbaum, F. Rhee, and C. S. Nabel, “Idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis and therapy,” Blood, vol. 123, no. 19, pp. 2924–2933, Mar 2014. View at Google Scholar
  6. T. S. Uldrick, M. N. Polizzotto, K. Aleman et al., “High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy,” Blood, vol. 117, no. 26, pp. 6977–6986, 2011. View at Publisher · View at Google Scholar
  7. C. Rokx, B. J. Rijnders, and J. A. van Laar, “Treatment of multicentric Castlemans disease in HIV-1 infected and uninfected patients: a systematic review,” Neth J Med, vol. 73, no. 5, pp. 202–210, Jun 2015. View at Google Scholar
  8. P. Nicoli, U. Familiari, M. Bosa, T. Allice, F. Mete, A. Morotti et al., “HHV8-positive, HIV-negative multicentric Castlemans disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma,” Int J Hematol., vol. 90, pp. 392–396, 2009. View at Google Scholar
  9. M. Bower, T. Powles, S. Williams, T. N. Davis, M. Atkins, S. Montoto et al., “Rituximab in HIV associated multicentric Castleman disease,” Ann Intern Med., vol. 147, no. 12, pp. 836–839, 2007. View at Google Scholar
  10. C. Hoffman, H. Schmid, M. Moller, C. Chris Teutsch, J. Lunzen, and S. Esser, “Improved outcome with Rituximab in patients with HIV – associated multicentric Castleman disease,” Blood, vol. 118, no. 13, pp. 3499–3503, Sep 2011. View at Google Scholar
  11. F. Van Rhee, R. S. Wong, M. Munshi, J. F. Rossi, K. e. XY, A. Fossa et al., “Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial,” Lancet Oncol, vol. 15, no. 9, pp. 966–974, Aug 2014. View at Google Scholar
  12. A. Nagao, S. Nakazawa, and H. Hanabusa, “Short term efficacy of the IL6 receptor antibody Tocilizumab in patients with HIV – associated multicentric Castleman disease: report of two cases,” Journal of Hematology and Oncology, vol. 7, p. 10, 2014. View at Publisher · View at Google Scholar